A once-weekly GLP-1 RA

A once-weekly GLP-1 RA

References

  1. Ozempic® (semaglutide) Product Monograph. Novo Nordisk Canada Inc. 2018.
  2. Tan Attlia and Timothy R Koch. Pathophysiology and Management of Diabetic Gastropathy. In: Opara E, ed. Nutrition and Diabetes: Pathophysiology and Management Boca Raton, FL. Taylor & Francis Group, LLC. 2006.
  3. Research Society for the Study of Diabetes in India. Diabetes Mellitus and Gastrointestinal System. In: Tripathy B, ed. RSSDI Textbook of Diabetes Mellitus Vol 1. 2 ed. New Delhi, India. Jaypee Brothers Medical Publishers (P) Ltd; 2012.
  4. The National Digestive Diseases Information Clearinghouse. Gastroparesis. 2012. Available at: http://www.syracusegastro.com/docs/Gastroparesis_508.pdf. Retrieved January, 2018.
  5. Arendt-Nielsen L, et al. Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res. 2006;23(1-2):37-43.
  6. Ley B. Diameter of a human hair. 1999. Available at: http://hypertextbook.com/facts/1999/BrianLey.shtml. Retrieved January, 2018.
  7. Alberta Health. Updates to the Alberta Drug Benefit List. 2019. Available at: http://www.health.alberta.ca/services/drug-benefit-list.html.
  8. Government of Ontario. Ontario Drug Benefit Formulary/Comparative Drug Index. 2019. Available at: http://www.health.gov.on.ca/en/pro/programs/drugs/how_drugs_approv/review_types.aspx. Retrieved March, 2020.
  9. Health PEI. P.E.I. Pharmacare Bulletin. 2019. Available at: https://www.princeedwardisland.ca/en/information/health-pei/pei-pharmacare-formulary. Retrieved March, 2020.
  10. RAMQ (official mark of the Régie de l'assurance maladie du Québec). List of Medications. 2020. Available at: https://www.ramq.gouv.qc.ca/SiteCollectionDocuments/liste_med/2020/liste_med_2020_03_04_en.pdf. Retrieved March 9, 2020.
  11. Government of New Brunswick. NB Drug Plans Formulary Update. 2019. Available at: https://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDrugPlan/NewBrunswickDrugPlansFormulary.pdf. Retrieved March, 2020.
  12. Newfoundland and Labrador Prescription Drug Program. Benefit List Updates. November 27, 2019.
  13. First Nations Inuit Health Branch. Non-insured Health Benefits: Drug Benefit List Indigenous Services Canada. 2020. Available at: https://www.sac-isc.gc.ca/DAM/DAM-ISC-SAC/DAM-HLTH/STAGING/texte-text/nihb_benefits-services_drugs_dbl-index_1573154657223_eng.pdf. Retrieved March, 2020.
  14. Government of Yukon. Yukon Drug Formulary. 2020. Available at: http://apps.gov.yk.ca/drugs/f?p=161:9010:3262035378058774::NO:9010::&cs=3EF884B905C536CFBE946A479D2076FE8. Retrieved March, 2020.
  15. Government of Northwest Territories. Health Benefits for Specified Disease Conditions Program. 2020. Available at: https://www.hss.gov.nt.ca/en/services/supplementary-health-benefits/extended-health-benefits-specified-disease-conditionsExtended. Retrieved March, 2020.
  16. Department of Health. EHB Full Coverage Plan. The Government of Nunavut. Available at: https://gov.nu.ca/health/information/ehb-full-coverage-plan. Retrieved March, 2020.
  17. Veterans Affairs Canada. Prescription Drug Program Details: Drug 02471469. 2019. Available at: https://www.veterans.gc.ca/eng/financial-support/medical-costs/treatment-benefits/poc10/search/form_detail/02471469. Retrieved March, 2020.
  18. Ahren B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2). Lancet Diabetes Endocrinol. 2017;5(5):341-354.
  19. Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): A double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834-844.
  20. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844.
  21. Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018;42(Suppl 1):S1-S325.

Contact Us

Novo Nordisk would like every healthcare practitioner to be able to obtain information as easily and quickly as possible.
If you need information about Ozempic®, please contact:

Novo Nordisk Canada Inc.
101-2476 Argentia Road
Mississauga, Ontario
L5N 6M1

Business hours are:
Monday to Friday from
8:30 a.m. to 5:00 p.m. EST

Main number:
905-629-4222
Toll-free:
1-800-465-4334

Main fax number:
905-629-8662
Toll-free fax number:
1-844-465-2225